Read by QxMD icon Read

Breast Cancer Research and Treatment

Omar Abdel-Rahman
OBJECTIVE: The aim of the current study is to evaluate the performance characteristics of the National Comprehensive Cancer Network (NCCN) staging recommendations for breast cancer with regard to the detection of lung, bone, and liver metastases. METHODS: Surveillance, epidemiology, and end points (SEER) database (2010-2015) was accessed, and patients with breast cancer and complete information about T stage and clinical N stage, ER status, Her2 status, and metastatic sites were extracted...
July 18, 2018: Breast Cancer Research and Treatment
Neal S McCall, Brittany A Simone, Minesh Mehta, Tingting Zhan, Kevin Ko, Kamila Nowak-Choi, Annaisabel Rese, Chantel Venkataraman, David W Andrews, Pramila R Anne', Adam P Dicker, Wenyin Shi, Nicole L Simone
PURPOSE: Metabolic dysregulation has been implicated as a molecular driver of breast cancer in preclinical studies, especially with respect to metastases. We hypothesized that abnormalities in patient metabolism, such as obesity and diabetes, may drive outcomes in breast cancer patients with brain metastases. METHODS: We retrospectively identified 84 consecutive patients with brain metastases from breast cancer treated with intracranial radiation therapy. Radiation was delivered as whole-brain radiation to a median dose of 3000 cGy or stereotactic radiosurgery to a median dose of 2100 cGy...
July 18, 2018: Breast Cancer Research and Treatment
Inbal Barnes-Kedar, Rinat Bernstein-Molho, Nava Ginzach, Shulamit Hartmajer, Tamar Shapira, Nurit Magal, Marina Lifshitc Kalis, Tamar Peretz, Mordechai Shohat, Lina Basel-Salmon, Eitan Friedman, Lily Bazak, Yael Goldberg
PURPOSE: BRCA1 and BRCA2 genotyping results have clinical implications for cancer risk assessment and targeted therapy. Current practice in Israel is to genotype for the predominant BRCA1/2 mutations first, followed by full gene analysis in eligible mutation-negative individuals. This work assessed the rate of non-predominant mutations in BRCA1/2 in ethnically diverse high-risk cases. METHODS: Breast and/or ovarian cancer patients who tested negative for the predominant BRCA1/2 mutations were referred for comprehensive BRCA1/2 genotyping if calculated risk for carrying a BRCA mutation was ≥ 10%...
July 16, 2018: Breast Cancer Research and Treatment
M Martín, J C de la Torre-Montero, S López-Tarruella, K Pinilla, A Casado, S Fernandez, Y Jerez, J Puente, I Palomero, R González Del Val, M Del Monte-Millan, T Massarrah, C Vila, B García-Paredes, J A García-Sáenz, A Lluch
In the original publication of the article, Table 1 was published with incorrect caption and values. The Table 1 with corrected caption and values is given in this Correction.
July 16, 2018: Breast Cancer Research and Treatment
M van Nuland, R A Vreman, R M T Ten Ham, A H M de Vries Schultink, H Rosing, J H M Schellens, J H Beijnen, A M Hövels
PURPOSE: Breast cancer is the most common malignancy in women worldwide. Recurrence rates in breast cancer are considered to be dependent on the serum concentration of endoxifen, the active metabolite of tamoxifen. The goal of this study is to investigate the cost-effectiveness of periodically monitoring serum concentrations of endoxifen in adjuvant estrogen receptor alfa (ERα) positive breast cancer patients treated with tamoxifen in the Netherlands. METHODS: A Markov model with disease-free survival (DFS), recurrent disease (RD), and death states was constructed...
July 13, 2018: Breast Cancer Research and Treatment
Katie M O'Brien, Therese Mooney, Patricia Fitzpatrick, Linda Sharp
PURPOSE: We examined whether demographic and tumour characteristics (including subtype) were different for women with breast cancer diagnosed via mammography screening compared with women with interval breast cancers, lapsed attenders of the screening programme and non-participants of the screening programme. In addition, we explored whether there were survival differences between the groups, taking into account lead time bias. METHODS: We used linked data from National Cancer Registry Ireland and the national breast screening programme BreastCheck...
July 13, 2018: Breast Cancer Research and Treatment
Mattia Rediti, Carlo Messina
No abstract text is available yet for this article.
July 12, 2018: Breast Cancer Research and Treatment
Malgorzata Banys-Paluchowski, Isabell Witzel, Sabine Riethdorf, Klaus Pantel, Brigitte Rack, Wolfgang Janni, Peter A Fasching, Bahriye Aktas, Sabine Kasimir-Bauer, Andreas Hartkopf, Erich-Franz Solomayer, Tanja Fehm, Volkmar Müller
PURPOSE: VEGF is one of the most important angiogenesis-stimulating cytokines and has been previously shown to be overexpressed in several solid cancers. The aim of the present study was to assess the clinical relevance of serum VEGF (sVEGF) in a large cohort of metastatic breast cancer patients and to explore the relationship between sVEGF and other blood-based biomarkers. METHODS: Two hundred fifty-three patients with metastatic breast cancer were enrolled in this prospective, multicentre study...
July 12, 2018: Breast Cancer Research and Treatment
Ashirbani Saha, Michael R Harowicz, Elizabeth Hope Cain, Allison H Hall, Eun-Sil Shelley Hwang, Jeffrey R Marks, Paul Kelly Marcom, Maciej A Mazurowski
PURPOSE: The purpose of the study was to define quantitative measures of intra-tumor heterogeneity in breast cancer based on histopathology data gathered from multiple samples on individual patients and determine their association with distant recurrence-free survival (DRFS). METHODS: We collected data from 971 invasive breast cancers, from 1st January 2000 to 23rd March 2014, that underwent repeat tumor sampling at our institution. We defined and calculated 31 measures of intra-tumor heterogeneity including ER, PR, and HER2 immunohistochemistry (IHC), proliferation, EGFR IHC, grade, and histology...
July 10, 2018: Breast Cancer Research and Treatment
Laura E Jansen, Wendy A Teft, Rhiannon V Rose, Daniel J Lizotte, Richard B Kim
PURPOSE: Tamoxifen is frequently prescribed to prevent breast cancer recurrence. Tamoxifen is a prodrug and requires bioactivation by CYP2D6. Tamoxifen use is often limited by adverse effects including severe hot flashes. There is paucity of prospectively collected data in terms of CYP2D6 genotype and measured tamoxifen, 4-hydroxytamoxifen and endoxifen concentrations in relation to hot flash severity during tamoxifen therapy. METHODS: We conducted a longitudinal prospective study of breast cancer patients on tamoxifen (n = 410)...
July 6, 2018: Breast Cancer Research and Treatment
Rosa Luraschi, Roberta Lazzari, Viviana Galimberti, Elena Rondi, Alessia Bazani, Giovanni Corso, Nicola Colombo, Rosalinda Ricotti, Cristiana Fodor, Mikolaj Winnicki, Maria Cristina Leonardi, Barbara Alicja Jereczek-Fossa, Federica Cattani
PURPOSE: To report in-vivo dosimetry in the infraclavicular region, a potential site of a cardiac implantable electronic device (CIED) and to evaluate the absorbed dose from intraoperative radiotherapy with electrons (ELIOT). METHODS: 27 non-cardiopathic breast cancer (BC) patients without CIED received quadrantectomy and ELIOT as partial breast irradiation. Before delivering ELIOT, two catheters, each containing eight thermoluminescent dosimeters (TLDs), were positioned in the infraclavicular region...
July 5, 2018: Breast Cancer Research and Treatment
Bertha Andrade Coelho, Sara de Pinho Cunha Paiva, Agnaldo Lopes da Silva Filho
PURPOSE: Mindfulness-based programs can reduce stress and help practitioners to have positive attitudes in their daily lives. This randomized controlled trial evaluated the impact of brief Mindfulness interventions on quantitative and qualitative stress parameters in patients undergoing imaging-guided breast biopsies. METHODS: Eighty-two women undergoing percutaneous imaging-guided breast biopsy were randomized into two groups: MBI group or standard care group. One week before the biopsy procedure, on the waiting room and during the biopsy procedure, the MBI group was exposed to mindfulness techniques and the standard care group received supportive dialogue from the biopsy team...
July 5, 2018: Breast Cancer Research and Treatment
Dejan Nikolić, Miroslav Granić, Nebojša Ivanović, Darko Zdravković, Aleksandra Nikolić, Violeta Stanimirović, Marija Zdravković, Srdjan Dikić, Marko Nikolić, Miroslav Djordjević
INTRODUCTION: Lesbian, gay, and bisexuals have unique healthcare needs. Breast cancer is leading cancer in women, worldwide, accounting for 25% of all cases. Annual incidence rates increased significantly in all countries and age groups. The occurrence of breast cancer is rare in transgender population. As they have very limited access to medical care, it is much less likely to pursue breast cancer screening than in other individuals not identified as transgender. REVIEW OF THE CASES FROM LITERATURE: Up to date, only 13 cases of the breast cancer transsexuals (female to male) have been reported in six published papers worldwide...
July 5, 2018: Breast Cancer Research and Treatment
Fernando A Angarita, Maryam Elmi, Yimeng Zhang, Nicole J Look Hong
PURPOSE: Older women (≥ 70 years old) with breast cancer undergo different treatments than young women. Studies have examined factors that influence this disparity, but synthesized patient-reported data are lacking in the literature. This study aims to identify, appraise, and synthesize the existing qualitative evidence on patient-reported factors influencing older women's decision to accept or decline breast cancer treatment. METHODS: A systematic review was performed in accordance with Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA) principles...
July 4, 2018: Breast Cancer Research and Treatment
Andrew Robinson, Osama Souied, A Brianne Bota, Nathalie Levasseur, Carol Stober, John Hilton, Dalia Kamel, Brian Hutton, Lisa Vandermeer, Sasha Mazzarello, Anil A Joy, Dean Fergusson, Sheryl McDiarmid, Mathew McInnes, Risa Shorr, Mark Clemons
IMPORTANCE: Systemic chemotherapy can be administered either through a peripheral vein (IV), or centrally through peripherally inserted central catheter (PICC), totally implanted vascular access devices (PORTs) or tunnelled cuffed catheters. Despite the widespread use of systemic chemotherapy in patients with breast cancer, the optimal choice of vascular access is unknown. OBJECTIVE: This systematic review evaluated complication rates and patient satisfaction with different access strategies for administering neo/adjuvant chemotherapy for breast cancer...
July 4, 2018: Breast Cancer Research and Treatment
My von Euler-Chelpin, Martin Lillholm, George Napolitano, Ilse Vejborg, Mads Nielsen, Elsebeth Lynge
PURPOSE: The currently recommended double reading of all screening mammography examinations is an economic burden for screening programs. The sensitivity of screening is higher for women with low breast density than for women with high density. One may therefore ask whether single reading could replace double reading at least for women with low density. We addressed this question using data from a screening program where the radiologists coded their readings independently. METHODS: Data include all screening mammography examinations in the Capital Region of Denmark from 1 November 2012 to 31 December 2013...
July 4, 2018: Breast Cancer Research and Treatment
Jiayu Wang, Binghe Xu, Wenna Wang, Xiaoyu Zhai, Xuelian Chen
PURPOSE: This meta-analysis was conducted to compare the efficacy and safety of fulvestrant with aromatase inhibitors in postmenopausal women with hormone receptor-positive (estrogen and/or progesterone receptor positive) advanced breast cancer. METHODS: Electronic databases were searched for randomized controlled trials comparing the efficacy and safety of fulvestrant with three aromatase inhibitors (anastrozole/letrozole/exemestane) published through August 31, 2017...
July 4, 2018: Breast Cancer Research and Treatment
Nashwa Kabil, Recep Bayraktar, Nermin Kahraman, Hamada A Mokhlis, George A Calin, Gabriel Lopez-Berestein, Bulent Ozpolat
BACKGROUND/PURPOSE: Triple-negative breast cancer (TNBC) is the most aggressive and chemoresistant subtype of breast cancer. Therefore, new molecular targets and treatments need to be developed to improve poor patient prognosis and survival. We have previously shown that eukaryotic elongation factor 2 kinase (eEF-2K) is highly expressed in TNBC cells, is associated with poor patient survival and prognosis, and promotes cell proliferation, migration, and invasion. In vivo targeting of eEF-2K significantly reduces the tumor growth of orthotopic TNBC xenograft mouse models, suggesting that eEF-2K may serve as a potential novel therapeutic target...
July 3, 2018: Breast Cancer Research and Treatment
Audrey Berthe, Marie Zaffino, Claire Muller, François Foulquier, Marine Houdou, Céline Schulz, Frédéric Bost, Elia De Fay, Sabine Mazerbourg, Stéphane Flament
PURPOSE: Cancer cells often elicit a higher glycolytic rate than normal cells, supporting the development of glycolysis inhibitors as therapeutic agents. 2-Deoxyglucose (2-DG) is used in this context due to its ability to compete with glucose. However, many studies do not take into account that 2-DG inhibits not only glycolysis but also N-glycosylation. Since there are limited publications on 2-DG mechanism of action in breast cancer, we studied its effects in breast cancer cell lines to determine the part played by glycolysis inhibition and N-linked glycosylation interference...
July 3, 2018: Breast Cancer Research and Treatment
Julie S Bedi, Rachel M Mayo, Khoa Truong, Liwei Chen, Lori Dickes, Windsor W Sherrill, Karyn Jones
PURPOSE: This study examines endocrine therapy (ET) non-initiation, non-adherence, and duration by age, race, temporal trend for South Carolina Medicaid-enrolled women diagnosed with estrogen receptor-positive breast cancer between 2000 and 2014 (N = 3830). METHODS: Age, race, relative risk, and median duration of ET use were compared. Temporal trends in ET non-initiation, non-adherence, and duration were observed using linear and logistic regression models, controlling for age and race...
July 3, 2018: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"